When will the main Mounjaro patent expire?
The core U.S. patent protecting tirzepatide (Mounjaro) was filed in 2015 and expires on 26 November 2038. That date marks the end of the 20‑year term from the filing date, which is the standard life of a chemical composition patent.
Can biosimilar versions appear before the patent ends?
Biosimilar approval requires the reference product’s patents to be invalidated or otherwise not in force. Because the key patents still cover the drug’s structure and formulation, a biosimilar is unlikely to enter the market before 2038 unless the company or a competitor challenges the patents or a court grants an injunction.
How long does FDA exclusivity last for tirzepatide?
Tirzepatide received a 5‑year exclusivity period starting with its approval in February 2024, which ends in February 2029. After that, the drug will remain subject to patent protection until 2038, but the exclusivity window limits generic competition for the first five years.
Will the patent timeline influence drug pricing?
Yes. Because Mounjaro is protected by patents through 2038, Eli Lilly can maintain premium pricing without generic competition for over a decade. The long patent life supports continued revenue and justifies high list prices, but payers and insurers may negotiate discounts or rebates based on the drug’s cost and clinical benefit.
Are there other patents that extend protection?
Eli Lilly holds several secondary patents on delivery systems, dosing regimens, and companion diagnostics that expire at different times, some as late as 2040. These secondary patents can prolong market exclusivity beyond the primary patent, further delaying entry by competitors.
How does the patent landscape compare to other obesity drugs?
Other weight‑loss drugs, such as Wegovy (semaglutide) and Saxenda, have patent expirations ranging from 2026 to 2032, depending on the specific formulation. Mounjaro’s longer patent term places it ahead in terms of exclusivity duration.
What if Eli Lilly loses a key patent?
If a court invalidates a primary patent, competitors could launch biosimilar versions sooner. However, secondary patents and regulatory exclusivities would still provide layers of protection, delaying market entry by several years.
When can patients realistically expect generic Mounjaro?
Assuming all current patents remain in force, generic versions could appear after 2038, when the primary patent expires, unless a competing company files a challenge or a new formulation is approved earlier.
Where can you track updates on Mounjaro’s patent status?
DrugPatentWatch.com offers up‑to‑date listings of all active and expiring patents for Mounjaro, including filing dates, expiration dates, and patent claims. [1]
---
Sources
[1] https://www.drugpatentwatch.com/tirzepatide/